Evidence map›Paper›PMID 40326783›Full record

ArticleBrain : a journal of neurology2025

Cell-specific Eif2b5 mutant mice: novel insights into roles of macroglia in vanishing white matter.

Javier Triñanes-Ramos, Marianna Bugiani, Gemma M van Rooijen-van Leeuwen, Juliette A Chevalier, Yuan Jiew Siu, Elise L H van Utenhove, Leoni Hoogterp, Diede Witkamp, Ellen Oudejans, Bastiaan Lodder and 5 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Javier Triñanes-RamosDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Marianna BugianiDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Gemma M van Rooijen-van LeeuwenDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Juliette A ChevalierDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Yuan Jiew SiuDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Elise L H van UtenhoveDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Leoni HoogterpDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Diede WitkampDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Ellen OudejansDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Bastiaan LodderAxonal Signaling Group, Netherlands Institute for Neurosciences, Royal Netherlands Academy for Arts and Sciences, Amsterdam, 1105 AZ, The Netherlands.
Maarten H P KoleAxonal Signaling Group, Netherlands Institute for Neurosciences, Royal Netherlands Academy for Arts and Sciences, Amsterdam, 1105 AZ, The Netherlands.ORCID 0000-0002-3883-5682
Gesine SaherDepartment of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, 37077, Germany.
Klaus-Armin NaveDepartment of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, 37077, Germany.
Truus E M AbbinkDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.
Marjo S van der KnaapDepartment of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands.ORCID 0000-0001-8912-0954

Funding

TOP 91217006ZonMw
6 · The paper itself

Abstract

Vanishing white matter (VWM) is a leukodystrophy caused by mutations in any of the genes encoding the subunits of the eukaryotic translation initiation factor 2B (eIF2B), a central factor in mRNA translation initiation and regulator of the translation rate during the integrated stress response. Clinically, VWM is characterized by chronic motor and cognitive decline and premature death. Neuropathology shows selective white matter involvement with dysmorphic, immature astrocytes and defective reactive astrogliosis, while oligodendrocytes show increased expression of immaturity and proliferation markers and neurons look normal. Expression of the ATF4 transcriptome is increased in the white matter. These characteristics have been replicated successfully in eIF2B mutant mouse models. Until now, the relative contribution of each cell type to the development of VWM has remained unclear. Understanding the vulnerability of specific cell types for VWM is crucial for understanding disease mechanisms and developing effective therapies. We generated astrocyte-, oligodendrocyte- and neuron-specific Eif2b5 conditional mouse lines to determine the role of each mutant cell type in the onset and development of the disease. We evaluated motor performance, white matter pathology and the expression of myelin-related proteins. We analysed astrocyte and oligodendrocyte density, maturity, morphology, proliferation and apoptosis. We investigated the expression of the integrated stress response-/ATF4-related genes and proteins, in addition to their localization within the glial cells. At age 9 months, we found that astrocyte-specific Eif2b5 conditional mice showed very mild ataxia, extensive intramyelinic vacuolization, normal density and maturity of oligodendrocytes, and high expression of ATF4-related genes. Oligodendrocyte-specific Eif2b5 conditional mice developed gait ataxia that matched the phenotype of the whole-body Eif2b5 mutant line. Myelin looked normal, but numerous axons were unmyelinated; astrocytes were reactive, and oligodendrocytes were immature and in cell cycle. The enhanced ATF4 transcriptome was minor compared with the astrocyte-specific lines. The neuron-specific Eif2b5 conditional line exhibited a very mild phenotype and none of the major characteristics of VWM. Our findings highlight a complex effect of Eif2b5 mutations in different brain cell types leading to the clinical and neuropathological characteristics of VWM. Oligodendrocytes are the major contributors to the development of ataxia, but astrocyte-specific Eif2b5 conditional mice display several histological and molecular key features of VWM. In conclusion, the view of a single cell population being responsible for the onset and development of VWM needs to be replaced by the concept of VWM as a disease involving diverse cell types.

Indexed as

AstrocytesEukaryotic Initiation Factor-2BLeukoencephalopathiesNeurogliaWhite MatterActivating Transcription Factor 4AnimalsDisease Models, AnimalMaleMiceMice, TransgenicMutationNeuronsOligodendrogliaActivating Transcription Factor 4Atf4 protein, mouseEukaryotic Initiation Factor-2Bconditional micegliavanishing white matter

Identifiers

PMID40326783
PMCPMC12588717

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.